PE20110028A1 - Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato - Google Patents

Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato

Info

Publication number
PE20110028A1
PE20110028A1 PE2010001111A PE2010001111A PE20110028A1 PE 20110028 A1 PE20110028 A1 PE 20110028A1 PE 2010001111 A PE2010001111 A PE 2010001111A PE 2010001111 A PE2010001111 A PE 2010001111A PE 20110028 A1 PE20110028 A1 PE 20110028A1
Authority
PE
Peru
Prior art keywords
isoxazole
dihydro
chloro
alkyl
metabotropic glutamate
Prior art date
Application number
PE2010001111A
Other languages
English (en)
Spanish (es)
Inventor
Joseph Cacciola
James Empfield
James Folmer
Angela M Hunter
Scott Throner
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20110028A1 publication Critical patent/PE20110028A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/08Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/083Clips, e.g. resilient
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/08Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound
    • A61B17/085Wound clamps or clips, i.e. not or only partly penetrating the tissue ; Devices for bringing together the edges of a wound with adhesive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/10Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods
    • A61B17/10Surgical instruments, devices or methods for applying or removing wound clamps, e.g. containing only one clamp or staple; Wound clamp magazines
    • A61B17/105Wound clamp magazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34Tobacco-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Surgery (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PE2010001111A 2008-06-06 2009-06-08 Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato PE20110028A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5948508P 2008-06-06 2008-06-06

Publications (1)

Publication Number Publication Date
PE20110028A1 true PE20110028A1 (es) 2011-02-11

Family

ID=41398335

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2010001111A PE20110028A1 (es) 2008-06-06 2009-06-08 Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato

Country Status (40)

Country Link
US (4) US7790760B2 (https=)
EP (2) EP2772492B1 (https=)
JP (2) JP5476371B2 (https=)
KR (1) KR20110020797A (https=)
CN (1) CN102105466B (https=)
AR (1) AR072016A1 (https=)
AU (1) AU2009255784B2 (https=)
BR (1) BRPI0913585A2 (https=)
CA (1) CA2726925A1 (https=)
CL (1) CL2010001348A1 (https=)
CO (1) CO6321239A2 (https=)
CR (1) CR11826A (https=)
CU (1) CU23883B1 (https=)
CY (1) CY1115301T1 (https=)
DK (1) DK2303872T3 (https=)
DO (1) DOP2010000375A (https=)
EA (2) EA201300342A1 (https=)
EC (1) ECSP10010662A (https=)
ES (1) ES2469837T3 (https=)
GT (1) GT201000342A (https=)
HK (1) HK1201255A1 (https=)
HN (1) HN2010002582A (https=)
HR (1) HRP20140451T1 (https=)
IL (1) IL209622A0 (https=)
MX (1) MX2010012949A (https=)
MY (1) MY156552A (https=)
NI (3) NI201000209A (https=)
NZ (1) NZ590344A (https=)
PE (1) PE20110028A1 (https=)
PL (1) PL2303872T3 (https=)
PT (1) PT2303872E (https=)
RS (1) RS53392B (https=)
SA (1) SA109300358B1 (https=)
SI (1) SI2303872T1 (https=)
SV (1) SV2010003751A (https=)
TW (3) TWI382027B (https=)
UA (1) UA107649C2 (https=)
UY (1) UY31870A (https=)
WO (1) WO2009148403A1 (https=)
ZA (1) ZA201008611B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
CN101801930B (zh) 2007-09-14 2013-01-30 億梅-ęØę£®åˆ¶čÆęœ‰é™å…¬åø 1,3-äŗŒå–ä»£ēš„-4-č‹ÆåŸŗ-1h-吔啶-2-酮
SI2203439T1 (sl) 2007-09-14 2011-05-31 Ortho Mcneil Janssen Pharm 1',3'-disubstituirani 4-fenil-3,4,5,6-tetrahidro-2H-1'H-(1,4')bipiridinil-2'-oni
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286
EP2344470B1 (en) 2008-09-02 2013-11-06 Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
WO2010043396A1 (en) 2008-10-16 2010-04-22 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
BRPI1010831A2 (pt) 2009-05-12 2016-04-05 Addex Pharmaceuticals Sa derivados de 1,2,4-triazolo[4,3-a]piridina e seu como moduladores alostƩricos positivos de receptores de mglur2
CN102439008B (zh) 2009-05-12 2015-04-29 ęØę£®åˆ¶čÆęœ‰é™å…¬åø 1,2,4-三唑并[4,3-a]å”å•¶č”ē”Ÿē‰©åŠå…¶ē”ØäŗŽę²»ē–—ęˆ–é¢„é˜²ē„žē»å’Œē²¾ē„žē—…ē—‡ēš„ē”Øé€”
US9271967B2 (en) 2010-11-08 2016-03-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
ES2536433T3 (es) 2010-11-08 2015-05-25 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostƩricos positivos de receptores mGluR2
AU2011328203B2 (en) 2010-11-08 2015-03-19 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv Ł…Ų±ŁƒŲØŲ§ŲŖ 6، 7- Ų«Ų§Ł†ŁŠ Ł‡ŁŠŲÆŲ±Łˆ ŲØŁŠŲ±Ų§Ų²ŁˆŁ„Łˆ [5،1-a] ŲØŁŠŲ±Ų§Ų²ŁŠŁ†- 4 (5 يد)- Ų§ŁˆŁ† ŁˆŲ§Ų³ŲŖŲ®ŲÆŲ§Ł…Ł‡Ų§ بصفة منظمات تفارغية Ų³Ł„ŲØŁŠŲ© لمستقبلات Ł…ŁŠŲ¬Ł„ŁˆŲ± 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv Ł…Ų±ŁƒŲØŲ§ŲŖ 2،1، 4- Ų«Ł„Ų§Ų«ŁŠ Ų²ŁˆŁ„Łˆ [3،4-a] ŲØŁŠŲ±ŁŠŲÆŁŠŁ† ŁˆŲ§Ų³ŲŖŲ®ŲÆŲ§Ł…Ł‡Ų§ بصفة منظمات تفارغية Ł…ŁˆŲ¬ŲØŲ© لمستقبلات Ł…ŁŠŲ¬Ł„ŁˆŲ± 2
MX386697B (es) 2014-01-21 2025-03-19 Janssen Pharmaceutica Nv Combinaciones que comprenden agonistas ortostericos o moduladores alostericos positivos del receptor glutamatergico metabotropico de subtipo 2 y su uso
ME03518B (me) 2014-01-21 2020-04-20 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore ili ortosterične agoniste metabotropnog glutamatergičnog receptora podtipa 2 i njihova primjena
EP3129345B1 (en) 2014-04-06 2023-03-15 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor positive allosteric modulators (pams) and uses thereof
KR101663662B1 (ko) * 2015-06-17 2016-10-14 ķ•œźµ­ź³¼ķ•™źø°ģˆ ģ—°źµ¬ģ› ėŒ€ģ‚¬ģ„± źø€ė£Øķƒ€ė©”ģ“ķŠø 수용첓 1에 ķ™œģ„±ģ„ ģ§€ė‹Œ ģ‹ ź·œ 아릓 ģ•„ģ“ģ†Œģ˜„ģ‚¬ģ”ø ģœ ė„ģ²“
US20170145002A1 (en) * 2015-11-25 2017-05-25 Astrazeneca Ab Deuterated isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE620654C (de) 1933-04-29 1935-10-24 Smith & Sons Ltd S Geschwindigkeitsanzeiger
US3993617A (en) 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
WO1992017448A1 (fr) 1991-04-01 1992-10-15 Kyowa Hakko Kogyo Co., Ltd. Derive de 3-methylenisoindolin-1-one
TW219935B (https=) 1991-12-25 1994-02-01 Mitsubishi Chemicals Co Ltd
EP0602814A1 (en) 1992-12-18 1994-06-22 Takeda Chemical Industries, Ltd. Crystal forms of optically active isoindolines and their use
US5681954A (en) 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
WO1997029079A1 (en) 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
EP0999208A4 (en) 1997-05-30 2001-08-08 Meiji Seika Kaisha NITROGEN-BASED HETEROCYCLIC COMPOUNDS AND MEDICINES FOR TREATING HYPERLIPEMIA THAT CONTAIN THEM
CN1158264C (zh) 1997-11-21 2004-07-21 NpsčÆē‰©ęœ‰é™å…¬åø ē”ØäŗŽę²»ē–—äø­ęž¢ē„žē»ē³»ē»Ÿē–¾ē—…ēš„ä»£č°¢ę€§č°·ę°Øé…øå—ä½“ę‹®ęŠ—å‰‚
US7166617B2 (en) 2000-02-29 2007-01-23 Mitsubishi Pharma Corporation Cyclic amide derivatives
BR0112856A (pt) 2000-07-31 2003-07-01 Smithkline Beecham Plc Método para o tratamento dos distúrbios, composto ou um sal ou solvato deste, processo para a preparação dos mesmos, composição farmacêutico, método de tratamento e/ou profilaxia de um ou mais dos distúrbios, uso de um composto, e, método para o tratamento de diabetes, grande depressão, depressão manìaca, ansiedade, esquizofrenia e distúrbios do sono, em mamìferos humanos e não humanos
CN101284773A (zh) 2001-08-09 2008-10-15 å°é‡ŽčÆå“å·„äøšę Ŗå¼ä¼šē¤¾ ē¾§é…øč”ē”Ÿē‰©åŠä»„å®ƒäøŗę“»ę€§ęˆåˆ†ēš„čÆå‰‚
WO2003087044A2 (en) 2002-04-09 2003-10-23 7Tm Pharma A/S Novel carboxamide compounds for use in mch receptor related disorders
FR2840302B1 (fr) 2002-06-03 2004-07-16 Aventis Pharma Sa Derives d'isoindolones, procede de preparation et intermediaire de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant
DE10238865A1 (de) 2002-08-24 2004-03-11 Boehringer Ingelheim International Gmbh Neue CarbonsƤureamid-Verbindungen mit MCH-antagonistischer Wirkung, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB0223232D0 (en) 2002-10-07 2002-11-13 Pfizer Ltd Chemical compounds
CA2519954A1 (en) 2003-03-26 2004-10-14 Merck & Co., Inc. Benzamide modulators of metabotropic glutamate receptors
GB0308025D0 (en) 2003-04-07 2003-05-14 Glaxo Group Ltd Compounds
US7129260B2 (en) 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
CA2542220A1 (en) 2003-10-22 2005-05-06 Eli Lilly And Company Novel mch receptor antagonists
US20080275062A1 (en) 2004-01-30 2008-11-06 David Harold Drewry Chemical Compounds
DE602005008558D1 (de) 2004-02-18 2008-09-11 Astrazeneca Ab Kondensierte heterocyclische verbindungen und deren verwendung als antagonisten des metabotropen reznkungen
CN1934094A (zh) 2004-03-05 2007-03-21 äø‡ęœ‰åˆ¶čÆę Ŗå¼ä¼šē¤¾ äŗŒčŠ³åŸŗå–ä»£ę‚ēŽÆ5å…ƒēŽÆč”ē”Ÿē‰©
AU2005219788B2 (en) 2004-03-05 2010-06-03 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and noxious organism control agent
SE0400970D0 (sv) 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
US20080096935A1 (en) 2004-10-25 2008-04-24 Pinkerton Anthony B Heterocyclic Indanone Potentiators of Metabotropic Glutamate Receptors
CA2598531A1 (en) 2005-02-24 2006-08-31 Merck & Co., Inc. Benzazole potentiators of metabotropic glutamate receptors
EP1893606A2 (en) 2005-05-18 2008-03-05 Addex Pharma SA Substituted oxadiazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
GB0510142D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds A1
TW200728277A (en) 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
JP5031745B2 (ja) * 2005-08-12 2012-09-26 ć‚¢ć‚¹ćƒˆćƒ©ć‚¼ćƒć‚« ć‚¢ć‚Æćƒćƒœćƒ©ć‚° ä»£č¬åž‹ć‚°ćƒ«ć‚æćƒŸćƒ³é…øå—å®¹ä½“å¢—å¼·ę€§ć‚¤ć‚½ć‚¤ćƒ³ćƒ‰ćƒ­ćƒ³
US7868008B2 (en) 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
JP5048675B2 (ja) 2005-09-27 2012-10-17 ć‚Øćƒ•ļ¼Žćƒ›ćƒ•ćƒžćƒ³āˆ’ćƒ© ćƒ­ć‚·ćƒ„ ć‚¢ćƒ¼ć‚²ćƒ¼ ļ½ļ¼§ļ½Œļ½•ļ¼²ļ¼’ć‚¢ćƒ³ć‚æć‚“ćƒ‹ć‚¹ćƒˆćØć—ć¦ć®ć‚Ŗć‚­ć‚µć‚øć‚¢ć‚¾ćƒŖćƒ«ćƒ”ćƒ©ć‚¾ćƒ­āˆ’ćƒ”ćƒŖćƒŸć‚øćƒ³é”ž
TW200804281A (en) 2006-02-16 2008-01-16 Astrazeneca Ab New metabotropic glutamate receptor-potentiating isoindolones
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab ļ˜–äŗŒå”‘č”ē”Ÿē‰©åŠå…¶ä½œē‚ŗä»£č¬åž‹éŗ©čƒŗé…øå—é«”å¢žę•ˆåŠ‘-ļ¼˜ļ¼”ļ¼’ä¹‹ē”Øé€”
US7790760B2 (en) * 2008-06-06 2010-09-07 Astrazeneca Ab Metabotropic glutamate receptor isoxazole ligands and their use as potentiators 286

Also Published As

Publication number Publication date
EP2303872B1 (en) 2014-04-16
CA2726925A1 (en) 2009-12-10
TW201514173A (zh) 2015-04-16
CU23883B1 (es) 2013-04-19
AU2009255784B2 (en) 2012-08-16
TW201247658A (en) 2012-12-01
EP2772492A1 (en) 2014-09-03
JP5476371B2 (ja) 2014-04-23
ECSP10010662A (es) 2011-01-31
DK2303872T3 (da) 2014-06-16
TWI477499B (zh) 2015-03-21
SV2010003751A (es) 2011-04-14
UA107649C2 (uk) 2015-02-10
CN102105466B (zh) 2014-10-15
TWI382027B (zh) 2013-01-11
DOP2010000375A (es) 2010-12-31
RS53392B (sr) 2014-10-31
KR20110020797A (ko) 2011-03-03
US7781434B2 (en) 2010-08-24
WO2009148403A1 (en) 2009-12-10
GT201000342A (es) 2015-02-16
NZ590344A (en) 2012-07-27
US20090306158A1 (en) 2009-12-10
JP2011522816A (ja) 2011-08-04
SA109300358B1 (ar) 2012-11-03
ZA201008611B (en) 2012-05-30
JP2014114312A (ja) 2014-06-26
AU2009255784A1 (en) 2009-12-10
NI201000209A (es) 2012-11-07
ES2469837T3 (es) 2014-06-20
NI201002091A (es) 2012-11-07
EP2303872A4 (en) 2012-03-21
CN102105466A (zh) 2011-06-22
US20100317662A1 (en) 2010-12-16
CU20100238A7 (es) 2011-11-15
CR11826A (es) 2011-02-04
US20100324044A1 (en) 2010-12-23
NI201002092A (es) 2012-11-07
PL2303872T3 (pl) 2014-08-29
HRP20140451T1 (hr) 2014-08-01
HK1155744A1 (en) 2012-05-25
MX2010012949A (es) 2010-12-15
EA018412B1 (ru) 2013-07-30
HN2010002582A (es) 2012-08-27
EA201001724A1 (ru) 2011-08-30
EA201300342A1 (ru) 2014-02-28
CL2010001348A1 (es) 2011-03-25
EP2303872A1 (en) 2011-04-06
IL209622A0 (en) 2011-02-28
SI2303872T1 (sl) 2014-06-30
US7790760B2 (en) 2010-09-07
EP2772492B1 (en) 2016-08-17
HK1201255A1 (en) 2015-08-28
BRPI0913585A2 (pt) 2015-10-27
MY156552A (en) 2016-02-26
JP5815765B2 (ja) 2015-11-17
US8148372B2 (en) 2012-04-03
CO6321239A2 (es) 2011-09-20
TW201002699A (en) 2010-01-16
UY31870A (es) 2010-01-29
US7888353B2 (en) 2011-02-15
PT2303872E (pt) 2014-06-23
CY1115301T1 (el) 2017-01-04
US20100022545A1 (en) 2010-01-28
AR072016A1 (es) 2010-07-28

Similar Documents

Publication Publication Date Title
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20141827A1 (es) Inhibidores de proteinas quinasas
CO6300954A2 (es) Derivados de tienopiridinonas como activadores de proteina quinasa activados por ampk
PE20090884A1 (es) Compuestos de indol como activadores de glucoquinasa
PE20120031A1 (es) Compuestos aril metil benzoquinazolinona como moduladores alostericos positivos del receptor m1
PE20091724A1 (es) Derivados de indol como moduladores del receptor nicotinico de acetilcolina alfa 7
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20081229A1 (es) Antagonistas de receptor de orexina de diazepam sustituido
PE20130155A1 (es) Derivados de ariletinilo
PE20121158A1 (es) Derivados de feniletinilo como moduladores alostericos positivos (map)
PE20141228A1 (es) Derivados de pirrolopirimidina y purina
PE20140207A1 (es) Composiciones y metodos para modular el fxr
PE20070585A1 (es) Derivados de sulfonamida como activadores de glucoquinasa
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
PE20090641A1 (es) Amidas heterociclicas
PE20080409A1 (es) Compuestos que modulan en el receptor cb2
PE20080150A1 (es) Derivados de piridinona n-aril y n-heteroaril sustituidos como antagonistas del receptor de la hormona concentradora de melanina (mch)
PE20110852A1 (es) Antagonistas del receptor de orexina de isonicotinamida
ECSP10010654A (es) Derivados de tienopiridonas como activadores de proteĆ­na quinasa activados por amp (ampk)
DOP2007000018A (es) Moduladores de indol sulfonamida de receptores de progesterona
PE20120561A1 (es) Compuestos que modulan selectivamente el receptor cb2
PE20071156A1 (es) COMPUESTOS DERIVADOS DE 4,5,6,7-TETRAHIDRO-1H-INDAZOL COMO POTENCIADORES DEL RECEPTOR DEL ACIDO a-AMINO-3-HIDROXI-5-METILISOXAZOL-4-PROPIONICO (AMPA)
PE20140934A1 (es) Derivados de pirazol
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20081665A1 (es) Antagonistas del receptor de dopamina 2 de rapida disociacion

Legal Events

Date Code Title Description
FA Abandonment or withdrawal